# Neoadjuvant Treatment of Upper Urinary and Muscular Invasive Bladder Urothelial Carcinoma

> **NCT04099589** · PHASE2 · UNKNOWN · sponsor: **Cancer Institute and Hospital, Chinese Academy of Medical Sciences** · enrollment: 64 (estimated)

## Conditions studied

- Upper Tract Urinary Carcinoma
- Muscle-invasive Bladder Cancer

## Interventions

- **DRUG:** Toripalimab

## Key facts

- **NCT ID:** NCT04099589
- **Lead sponsor:** Cancer Institute and Hospital, Chinese Academy of Medical Sciences
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2019-10-01
- **Primary completion:** 2022-10-01
- **Final completion:** 2022-10-01
- **Target enrollment:** 64 (ESTIMATED)
- **Last updated:** 2022-03-29

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04099589

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04099589, "Neoadjuvant Treatment of Upper Urinary and Muscular Invasive Bladder Urothelial Carcinoma". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT04099589. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*